Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Contract-Based Intangible Assets Contract-Based Intangible Assets [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Loxo Oncology, Inc. Loxo Oncology, Inc. [Member] Loxo Oncology, Inc. [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Acquired in-process research and development Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development Definite-lived intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Deferred income taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other assets and liabilities - net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Goodwill Goodwill Total consideration transferred - net of cash acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Equity [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Foreign currency translation gains/losses Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Unrealized net gains/losses on securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member] Defined benefit pension and retiree health benefit plans Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Effective portion of cash flow hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Milestone Payments, Development and Regulatory, Capitalized, Cumulative Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member] Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] Royalty Agreement Terms Royalty Agreement Terms [Member] Milestone Payments, Development and Regulatory, Capitalized (Deferred) Milestone Payments, Development and Regulatory, Capitalized (Deferred) [Member] Milestone Payments, Development and Regulatory, Capitalized [Member] Milestone Payments, Development and Regulatory, Expensed Milestone Payments, Development and Regulatory, Expensed [Member] Milestone Payments, Development and Regulatory, Expensed [Member] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Research and Development Exp Research and Development Expense [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Basaglar Basaglar [Member] Basaglar [Member] Jardiance Jardiance [Member] Jardiance [Member] Trajenta Trajenta (BI) [Member] Trajenta (BI) [Member] Olumiant® Olumiant [Member] Olumiant [Member] Tanezumab Tanezumab [Member] Tanezumab [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] U.S. UNITED STATES Europe Europe [Member] Japan JAPAN Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Milestones (deferred) capitalized Collaborative Arrangement, Rights and Obligations, Terms Terms or rights and obligations under collaborative arrangements. Revenue Revenues Collaborative arrangement, rights and obligations, percentage Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. R&D expense Research and Development Expense Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Elanco Animal Health Incorporated Elanco Animal Health Incorporated [Member] Elanco Animal Health Incorporated [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Noncontrolling interest, ownership percentage by parent Noncontrolling Interest, Ownership Percentage by Parent Gain on disposition of business Gain (Loss) on Disposition of Business Transitional services agreement, term Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term Legacy Antibiotic Medicines and Manufacturing Facility in Suzhou, China Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member] Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member] Disposal Group, Held-for-sale, Not Discontinued Operations Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Eddingpharm Eddingpharm [Member] Eddingpharm [Member] Centrexion Therapeutics Corporation Centrexion Therapeutics Corporation [Member] Centrexion Therapeutics Corporation [Member] CNTX-0290 CNTX-0290 [Member] CNTX-0290 [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Acquired in-process research and development Acquired in-process research and development The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT) Purchase price Business Combination, Consideration Transferred Number of medicines, rights to, agreed to be sold Number Of Medicines, Rights To, Agreed To Be Sold Number Of Medicines, Rights To, Agreed To Be Sold Disposal group, not discontinued operation, deposit to be received Disposal Group, Not Discontinued Operation, Deposit To Be Received Disposal Group, Not Discontinued Operation, Deposit To Be Received Disposal group, not discontinued operation, payment to be received Disposal Group, Not Discontinued Operation, Payment To Be Received Disposal Group, Not Discontinued Operation, Payment To Be Received License and research collaboration agreement, upfront fee Collaborative Agreement, Upfront Fee Collaborative Agreement, Upfront Fee Statement of Comprehensive Income [Abstract] Statement [Table] Statement [Table] Operating Activities [Axis] Operating Activities [Axis] Operating Activities [Domain] Operating Activities [Domain] Discontinued Operations Discontinued Operations [Member] AOCI Attributable to Parent AOCI Attributable to Parent [Member] AOCI Attributable to Noncontrolling Interest AOCI Attributable to Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Accumulated other comprehensive income Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Leases [Abstract] Lessee, lease, remaining lease term (up to) Lessee, Lease, Remaining Lease Term Lessee, Lease, Remaining Lease Term Operating lease cost Operating Lease, Cost Fair Value Disclosures [Abstract] Schedule of effects of risk-management instruments were recognized in other–net, (income) expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Summary certain fair value information Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary certain fair value information, liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Fair value, by balance sheet grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Summary the contractual maturities of our investments in debt securities measured at fair value Debt Securities, Available-for-sale [Table Text Block] Summary of the amount of unrealized gains and losses (pretax) recognized in our statement of operations for equity securities Unrealized Gain (Loss) on Investments [Table Text Block] Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities Gain (Loss) on Securities [Table Text Block] Revenue from Contract with Customer [Abstract] Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Schedule of amounts recorded for contract liabilities Contract with Customer, Asset and Liability [Table Text Block] Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Revenue, information used to determine revenue recognized, change in accounting estimate, percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue Revenue from Contract with Customer [Text Block] Description of Derivative Risk Management Policy Derivatives, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Contingencies Commitments and Contingencies Disclosure [Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Pension contributions Payment for Pension Benefits Estimated future employer contributions in current fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Payment for additional discretionary funding Payment for Pension Benefits, Additional Discretionary Funding Payment for Pension Benefits, Additional Discretionary Funding Contract liabilities Contract with Customer, Liability Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Senior Notes Due March 2029 Senior Notes Due March 2029 [Member] Senior Notes Due March 2029 [Member] Senior Notes Due March 2039 Senior Notes Due March 2039 [Member] Senior Notes Due March 2039 [Member] Senior Notes Due March 2049 Senior Notes Due March 2049 [Member] Senior Notes Due March 2049 [Member] Senior Notes Due March 2059 Senior Notes Due March 2059 [Member] Senior Notes Due March 2059 [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Senior Notes Senior Notes [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Buy U.S. Dollars Sell Euros Buy Us Dollar Sell Euro [Member] Foreign Currency Forward commitment to Buy US dollar Sell euro Buy Euros Sell U.S. Dollars Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Buy U.S. Dollars Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Buy British Pounds and Sell U.S. Dollars Buy British Pound and Sell US Dollars [Member] Buy British Pound and Sell US Dollars [Member] Swap U.S. Dollars to Euro Swap U.S. Dollars To Euro [Member] Swap U.S. Dollars To Euro [Member] Swap Swiss Francs to U.S. Dollars Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Swap U.S. Dollars to British Pounds Swap U.S. Dollars To British Pounds [Member] Swap U.S. Dollars To British Pounds [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative liability, notional amount Derivative Liability, Notional Amount Derivative asset, notional amount Derivative Asset, Notional Amount Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Long-term debt, including current portion Long-term Debt Derivatives used in net investment hedge, net of tax Derivatives used in Net Investment Hedge, Net of Tax Derivative, notional amount Derivative, Notional Amount Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted Description of Derivative Activity Volume Percent Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2 Debt instrument, face amount Debt Instrument, Face Amount Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Proceeds from issuance of notes Proceeds from Issuance of Debt Interest rate cash flow hedge losses to be reclassified during next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Equity securities, net unrealized gains and (losses) Equity Securities, FV-NI, Gain (Loss) OTTI recognized Other than Temporary Impairment Losses, Investments Available-for-sale, percentage of nonperforming assets Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets Amount of receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Restructuring and Related Activities [Abstract] Asset Impairment, Restructuring, and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Cover page. Document Information [Table] Document Information [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock (no par value) Common Class A [Member] 1.000% Notes Due June 2, 2022 1.000% Notes Due June 2, 2022 [Member] 1.000% Notes Due June 2, 2022 [Member] 7 1/8% Notes Due June 1, 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] 1.625% Notes Due June 2, 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] 2.125% Notes Due June 3, 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] 6.77% Notes Due January 1, 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Document Information [Line Items] Document Information [Line Items] Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Statement of Cash Flows [Abstract] Discontinued operations cash Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Income Statement [Abstract] Revenue (Note 2) Costs, expenses, and other: Costs and Expenses [Abstract] Cost of sales Cost of Goods and Services Sold Research and development Marketing, selling, and administrative Selling, General and Administrative Expense Acquired in-process research and development (Note 3) Asset impairment, restructuring, and other special charges (Note 6) Restructuring, Settlement and Impairment Provisions Other–net, (income) expense (Note 13) Nonoperating Income (Expense) Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income taxes (Note 9) Income Tax Expense (Benefit) Net income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net income (loss) from discontinued operations (Note 5) Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net income (loss) Net Income (Loss) Attributable to Parent Earnings (loss) per share: Earnings Per Share [Abstract] Earnings (loss) from continuing operations - basic (usd per share) Income (Loss) from Continuing Operations, Per Basic Share Earnings (loss) from discontinued operations - basic (usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Earnings (loss) per share - basic (usd per share) Earnings Per Share, Basic Earnings (loss) from continuing operations - diluted (usd per share) Income (Loss) from Continuing Operations, Per Diluted Share Earnings (loss) from discontinued operations - diluted (usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Earnings (loss) per share - diluted (usd per share) Earnings Per Share, Diluted Shares used in calculation of earnings (loss) per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Statement of Financial Position [Abstract] Assets Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents (Note 7) Cash and Cash Equivalents, at Carrying Value Short-term investments (Note 7) Short-term Investments Accounts receivable, net of allowances of $23.7 (2019) and $24.1 (2018) Accounts Receivable, after Allowance for Credit Loss, Current Other receivables Other Receivables, Net, Current Inventories Inventory, Net Prepaid expenses and other Prepaid Expense, Current Current assets of discontinued operations (Note 5) Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current Investments (Note 7) Long-term Investments Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Deferred tax assets Deferred Income Tax Assets, Net Sundry Other Assets, Noncurrent Property and equipment, net of accumulated depreciation of $8,956.3 (2019) and $8,666.9 (2018) Property, Plant and Equipment, Net Operating lease assets (Note 8) Operating Lease, Right-of-Use Asset Noncurrent assets of discontinued operations (Note 5) Disposal Group, Including Discontinued Operation, Assets, Noncurrent Total assets Assets Liabilities and Equity Liabilities and Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Short-term borrowings and current maturities of long-term debt Debt, Current Accounts payable Accounts Payable, Current Employee compensation Employee-related Liabilities, Current Sales rebates and discounts Sales rebates and discounts Sales rebates and discounts Dividends payable Dividends Payable, Current Income taxes payable Taxes Payable, Current Other current liabilities Other Liabilities, Current Current liabilities of discontinued operations (Note 5) Disposal Group, Including Discontinued Operation, Liabilities, Current Total current liabilities Liabilities, Current Other Liabilities Liabilities, Noncurrent [Abstract] Long-term debt Long-term Debt, Excluding Current Maturities Noncurrent operating lease liabilities (Note 8) Operating Lease, Liability, Noncurrent Accrued retirement benefits (Note 10) Liability, Defined Benefit Plan, Noncurrent Long-term income taxes payable Accrued Income Taxes, Noncurrent Deferred tax liabilities Deferred Income Tax Liabilities, Net Other noncurrent liabilities Other Liabilities, Noncurrent Noncurrent liabilities of discontinued operations (Note 5) Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Total other liabilities Liabilities, Noncurrent Commitments and Contingencies (Note 11) Commitments and Contingencies Eli Lilly and Company Shareholders’ Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Employee benefit trust Common Stock, Shares Held in Employee Trust Accumulated other comprehensive loss (Note 12) Accumulated Other Comprehensive Income (Loss), Net of Tax Cost of common stock in treasury Treasury Stock, Value Total Eli Lilly and Company shareholders’ equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total equity Total liabilities and equity Liabilities and Equity Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Schedule of components of other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of reclassifications out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] U.S. government and agency securities US Government Agencies Debt Securities [Member] Corporate debt securities Corporate Debt Securities [Member] Mortgage-backed securities Collateralized Mortgage Backed Securities [Member] Asset-backed securities Asset-backed Securities [Member] Other securities Other Debt Obligations [Member] Other securities Other Equity Securities [Member] Other Equity Securities [Member] Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Equity method investments Equity Method And Other Investments [Member] Equity Method and Other Investments [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Amount Reported Value Measurement [Member] Cost Portion at Other than Fair Value Measurement [Member] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Short-term investments, debt securities Debt Securities, Available-for-sale, Current Noncurrent investments, debt securities Debt Securities, Available-for-sale, Noncurrent Equity securities Equity Securities, FV-NI Equity investments without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Equity method investments Other Long-term Investments Noncurrent investments Short-term commercial paper borrowings Commercial Paper Long-term debt, including current portion Schedule of net pension and retiree health benefit (income) cost Schedule of Net Benefit Costs [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Acquisitions and Divestiture Mergers, Acquisitions and Dispositions Disclosures [Text Block] Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Continuing Operations Continuing Operations [Member] Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Beginning balance Reclassification due to adoption of new accounting standard Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Ending balance Net income (loss) from discontinued operations AC Immune SA AC Immune SA [Member] AC Immune SA [Member] ImmuNext, Inc. ImmuNext, Inc. [Member] ImmuNext, Inc. [Member] Avidity Biosciences, Inc. Avidity Biosciences, Inc. [Member] Avidity Biosciences, Inc. [Member] Sigilon Therapeutics Sigilon Therapeutics [Member] Sigilon Therapeutics [Member] AurKa Pharma, Inc. Aurka Pharma [Member] Aurka Pharma [Member] ARMO Biosciences, Inc. ARMO Biosciences, Inc. [Member] ARMO Biosciences, Inc. [Member] Severance Severance Costs Asset impairment and other special charges Asset Impairment Charges Total asset impairment, restructuring, and other special charges Schedule of the amounts recognized for assets acquired and liabilities assumed as of the acquisition date Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of asset acquisition Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Plaintiff Appealing Decision of Court Plaintiff Appealing Decision of Court [Member] Plaintiff Appealing Decision of Court [Member] Brazil BRAZIL Alimta® Alimta [Member] Alimta [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case [Domain] Dr Reddy's Lab Dr Reddy's Lab [Member] Dr Reddy's Lab [Member] Japanese Administrative Proceedings Japanese Administrative Proceedings [Member] Japanese Administrative Proceedings [Member] Employee Litigation Employee Litigation [Member] Employee Litigation [Member] Employee Litigation, Similar Lawsuit One Employee Litigation, Similar Lawsuit One [Member] Employee Litigation, Similar Lawsuit One [Member] Employee Litigation, Similar Lawsuit Two Employee Litigation, Similar Lawsuit Two [Member] Employee Litigation, Similar Lawsuit Two [Member] Adocia S.A Adocia S.A [Member] Adocia S.A [Member] Insulin Pricing Litigation and Proceedings Insulin Pricing Litigation And Proceedings [Member] Insulin Pricing Litigation And Proceedings [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of new application Number of New Application Number of New Application Number of defendants Loss Contingency, Number of Defendants Number of companies Number of Companies Number of Companies Claims settled and dismissed Loss Contingency, Claims Settled and Dismissed, Number Number of demands Loss Contingency, Number of Demands Loss Contingency, Number of Demands Number of patents Number of Patents Number of Patents Damages awarded, value Loss Contingency, Damages Awarded, Value Number of lawsuits Loss Contingency, Number of Lawsuits Number of lawsuits in a particular litigation or loss contingency. Number of similar lawsuits Loss Contingency, Number Of Similar Lawsuits Loss Contingency, Number Of Similar Lawsuits Number of individuals Number of Individuals Number of Individuals Amount of claim Loss Contingency, Amount of Claim Loss Contingency, Amount of Claim Gain contingency, unrecorded amount Gain Contingency, Unrecorded Amount Number of requests for information from Committee on Energy and Commerce Loss Contingency, Number Of Requests For Information Loss Contingency, Number Of Requests For Information Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Foreign currency-denominated notes Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Interest rate contracts Interest Rate Contract [Member] Foreign currency exchange contracts Foreign Exchange Contract [Member] Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Forward-starting interest rate swaps Interest Rate Swap [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Net investment hedges Net Investment Hedging [Member] Cash flow hedges Cash Flow Hedging [Member] Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain(loss) Recognized Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Basis of Presentation and Implementation of New Financial Accounting Standards Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule of significant milestones and revenue recognized Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Nonoperating Income (Expense) [Abstract] Other–Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Operating lease assets Reclassification of deferred rent net of prepaid rent, as a component of the operating lease asset Operating lease liabilities Operating Lease, Liability Schedule of other–net, (income) expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Interest expense Interest Expense Interest income Investment Income, Interest Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Other income Other Nonoperating Income (Expense) Other–net, (income) expense Business Combinations Policy Business Combinations Policy [Policy Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Actuarial losses, net Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Other, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Other–net, (income) expense Total before tax Tax benefit Reclassifications from continuing operations (net of tax) Reclassifications from discontinued operations (net of tax) Net of tax Debt Securities Contractual Maturities Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Total Debt Securities, Available-for-sale Less Than 1 Year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value 1-5 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value 6-10 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value More Than 10 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Leases Lessee, Operating Leases [Text Block] Leases Lessee, Finance Leases [Text Block] Endocrinology Endocrinology [Member] Revenue to unaffiliated customers, Endocrinology Trulicity® Trulicity [Member] [Member] Trulicity [Member] [Member] Humalog® Humalog [Member] Humalog [Member] Forteo® Forteo [Member] Forteo [Member] Humulin® Humulin [Member] Humulin [Member] Basaglar® Other Endocrinology Other Endocrinology [Member] Other Endocrinology [Member] Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Cyramza® Cyramza [Member] Cyramza [Member] Erbitux® Erbitux [Member] Erbitux [Member] Verzenio® Verzenio [Member] Verzenio [Member] Other Oncology Other Oncology [Member] Other Oncology [Member] Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Cymbalta® Cymbalta [Member] Cymbalta [Member] Zyprexa® Zyprexa [Member] Zyprexa [Member] Strattera® Strattera [Member] Strattera [Member] Emgality® Emgality [Member] Emgality [Member] Other Neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Immunology Immunology [Member] Immunology [Member] Taltz® Taltz [Member] Taltz [Member] Other Other Product, Total [Member] Other Product, Total [Member] Cialis® Cialis [Member] Cialis [Member] Other Other Product [Member] Other Product [Member] Outside U.S. Non-US [Member] Retirement Benefits [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Defined Benefit Pension Plans Pension Plan [Member] Retiree Health Benefit Plans Other Postretirement Benefits Plan [Member] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Service cost Defined Benefit Plan, Service Cost Interest cost Defined Benefit Plan, Interest Cost Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Recognized actuarial loss Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Fair Value Hedging Fair Value Hedging [Member] Cash Flow Hedging Other receivables Derivative Asset, Current Sundry Derivative Asset, Noncurrent Other current liabilities Derivative Liability, Current Other noncurrent liabilities Derivative Liability, Noncurrent Year 1 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months Year 2 Lessee, Operating Lease, Liability, Payments, Due Year Two Year 3 Lessee, Operating Lease, Liability, Payments, Due Year Three Year 4 Lessee, Operating Lease, Liability, Payments, Due Year Four Year 5 Lessee, Operating Lease, Liability, Payments, Due Year Five After Year 5 Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Gain related to disposition of Elanco (Note 5) Depreciation and amortization Depreciation, Depletion and Amortization Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Net purchases of property and equipment Payments for (Proceeds from) Productive Assets Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-term Investments Purchases of short-term investments Payments to Acquire Short-term Investments Proceeds from sales of noncurrent investments Proceeds from Sale of Long-term Investments Purchases of noncurrent investments Payments to Acquire Long-term Investments Cash paid for acquisitions, net of cash acquired (Note 3) Payments to Acquire Businesses, Net of Cash Acquired Purchase of in-process research and development Purchased in-process research and development The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS). Other investing activities, net Payments for (Proceeds from) Other Investing Activities Net Cash Provided by (Used for) Investing Activities Net Cash Provided by (Used in) Investing Activities Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Dividends paid Payments of Dividends Net change in short-term borrowings Proceeds from (Repayments of) Short-term Debt Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Repayments of long-term debt Repayments of Long-term Debt Purchases of common stock Payments for Repurchase of Common Stock Other financing activities, net Proceeds from (Payments for) Other Financing Activities Net Cash Provided by (Used for) Financing Activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at January 1 (includes $677.5 (2019) and $324.4 (2018) of discontinued operations) Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations Cash and Cash Equivalents at June 30 (includes $322.1 (2018) of discontinued operations) Net product revenue Product [Member] Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Royalty Royalty [Member] Receivables, Net, Current [Abstract] Allowances for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Statement of Stockholders' Equity [Abstract] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Employee Benefit Trust Trust for Benefit of Employees [Member] Accumulated Other Comprehensive Loss Common Stock in Treasury Treasury Stock [Member] Noncontrolling Interests Noncontrolling Interest [Member] Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Issued Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other comprehensive income (loss), net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Cash dividends declared per share Dividends, Cash Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Stock-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Adoption of new accounting standards Acquisition of common stock in exchange offer (in shares) Stock Acquired During Period, Shares, Exchange Offer Stock Acquired During Period, Shares, Exchange Offer Acquisition of common stock in exchange offer Stock Acquired During Period, Value, Exchange Offer Stock Acquired During Period, Value, Exchange Offer Deconsolidation of Elanco Impact on Equity of Sale of Noncontrolling Interest in Subsidiary Impact on Equity of Sale of Noncontrolling Interest in Subsidiary Other Stockholders' Equity, Other Ending balance (in shares) Proceeds from sales Proceeds from Sale of Equity and Available for Sale Securities Proceeds from Sale of Equity and Available for Sale Securities Realized gross gains on sales Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Realized gross losses on sales Available for sale Securities and Equity Securities, FV-NI, Realized Loss Available for sale Securities and Equity Securities, FV-NI, Realized Loss Cash dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount The components of the charges included in asset impairment, restructuring, and other special charges Restructuring and Related Costs [Table Text Block] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Financial Instruments Fair Value Disclosures [Text Block] Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Operating cash flows from operating leases Operating Lease, Payments Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Retirement Benefits Pension and Other Postretirement Benefits Disclosure [Text Block] Summary of discontinued operations in consolidated condensed financial statements Disposal Groups, Including Discontinued Operations [Table Text Block] Schedule of impact of leases to consolidated condensed financial statements Lease, Cost [Table Text Block] Schedule of maturities of operating lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Inventories Disposal Group, Including Discontinued Operation, Inventory, Current Other current assets Disposal Group, Including Discontinued Operation, Other Assets, Current Current assets of discontinued operations Goodwill Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent Other intangibles, net Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent Property and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent Other assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Noncurrent assets of discontinued operations Current liabilities of discontinued operations Long-term debt Disposal Group, Including Discontinued Operation, Debt, Noncurrent Disposal Group, Including Discontinued Operation, Debt, Noncurrent Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Noncurrent liabilities of discontinued operations Unrealized gross gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Unrealized gross losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair value of securities in an unrealized gain position Debt Securities, Available-for-sale, Unrealized Gain Position Debt Securities, Available-for-sale, Unrealized Gain Position Fair value of securities in an unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position Net income (loss) Other comprehensive income (loss), net of tax (Note 12) Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] ARMO and AurKa ARMO and AurKa [Member] ARMO and AurKa [Member] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] Tax Year 2013 Tax Year 2013 [Member] Tax Year 2015 Tax Year 2015 [Member] Tax Years 2013 to 2015 Tax Years 2013 To 2015 [Member] Tax Years 2013 To 2015 [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Effective income tax rate, percentage Effective Income Tax Rate Reconciliation, Percent Income tax expense Income before income taxes Nondeductible expense, research and development, amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Income tax year under examination Income Tax Examination, Year under Examination Decrease in unrecognized tax benefits is reasonably possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Income tax settlement payment Payments For Income Tax Settlements Payments For Income Tax Settlements